Press Releases July 20, 2026 04:09 PM

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

SI-BONE Announces Q2 2026 Earnings Release Date and Conference Call

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SIBN

SI-BONE, Inc., a leader in procedural solutions for compromised bone, announced it will report its second quarter 2026 financial results on August 3, 2026, followed by a management conference call. The company highlights its expertise in spinopelvic anatomy technology and over 150,000 procedures performed since 2009.

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SIBN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SI-BONE will release Q2 2026 financial results on August 3, 2026, with a subsequent conference call.
  • The company specializes in procedural solutions addressing clinical challenges related to compromised bone and spinopelvic anatomy.
  • SI-BONE has a strong clinical foundation, supported by multiple randomized controlled trials and numerous peer-reviewed publications.

SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 185 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved

Contact

Saqib Iqbal: [email protected]


Risks

  • Financial performance for Q2 2026 is uncertain prior to the earnings announcement, which may impact stock price.
  • Dependence on the adoption of SI-BONE's technologies and clinical acceptance in the healthcare market.
  • Potential regulatory or competitive challenges in the medical device sector targeting bone-related conditions.

More from Press Releases

New Fluke TLPV2 Solar Test Lead Set Eliminates Risky Live-Box Voltage Measurements in Operating PV Systems Jul 21, 2026 CoinShares Unveils UCITS Platform, Expanding Access to Europe's €26.3 Trillion Regulated Fund Ecosystem Jul 21, 2026 Enigmatig Limited Invests in KUNGFULAND, First-Scripted Feature-Length Action-Comedy Singapore and Canada Treaty Co-Production Using Virtual Production Jul 21, 2026 Statement of no intention to make an offer for Brera Holdings plc (the “Company”) Jul 21, 2026 Zoom appoints Carlos Quaderi as Head of APAC to drive next phase of AI-powered growth Jul 20, 2026